Effect of Hepatitis C Virus infection on the right ventricular functions, pulmonary artery pressure and pulmonary vascular resistance.

Canan Demir¹, Mehmet Demir²

¹Departments of Infectious Disease Bursa Şevket Yılmaz Education and Research Hospital, Bursa, Turkey
²Departments of Cardiology Bursa Yüksek İhtisas Education and Research Hospital, Bursa, Turkey

Abstract

Infection with hepatitis C virus (HCV) is one of the most common causes of viral hepatitis worldwide. Multiple extrahepatic manifestations of HCV infection have been recognized. In this study we aimed to examine right ventricular systolic function and pulmonary artery pressure in HCV patients. The study included 50 HCV patients (mean age; 34±12 years) and 50 normal persons (mean age; 28±11 years) as control group. Transthoracic echocardiography was performed on all the participants. Right ventricular systolic parameters, pulmonary artery pressure and pulmonary vascular resistance (PVR) were compared between these two groups. In patients with HCV, the right ventricular fractional area change (RV FAC), tricuspid annular plane excursion (TAPSE) and RV myocardial systolic velocity (Sv) values were lower than the control group (31 ± 10 vs 48 ±12 %; 13.5 ± 1.5 vs 19.2 ± 3.4 mm and 8.3 ± 1.1 vs 17.7 ± 3.3 cm/s all p values<0.001; respectively); the right atrium (RA) and RV diameters were higher than controls (4.8 ± 1.3 vs 3.6 ± 0.6 cm, p<0.001; 4.4 ± 0.8 vs 3.3 ± 0.5cm p<0.001, respectively). Additionally systolic pulmonary artery pressure and PVR were higher than controls (36.3 ± 9.9 vs 23 ± 7.8 mmHg, 3.5 ± 1.1 vs 2.1± 0.8; p<0.001, respectively). Conclusion: The findings showed that HCV infection may be associated with right ventricular systolic dysfunction and pulmonary hypertension.

Keywords: Hepatitis C virus; cardiomyopathy; myocarditis; pulmonary artery pressure; pulmonary vascular resistance.

Accepted July 07 2014

Introduction

The Hepatitis C virus (HCV) infection is a major public health problem worldwide. Additionally, HCV infection has been associated with extrahepatic involvements such as Sjögren’s syndrome, cryoglobulinemia, glomerulonephritis, lichen planus, and Hashimoto’s thyroiditis [1,2]. It is also considered that there is a relation between HBV and HCV and oronary artery disease and heart failure [3-6].

Recent studies revealed that there is a relation between HCV and lung disease such as pulmonary fibrosis, chronic obstructive pulmonary disease and interstitial pneumonitis [7,8].

Several viruses, mainly parvovirus, adenovirus and enterovirus, may infect the myocardium. Since these agents cannot be found in many patients with myocarditis, other etiologic agents have been searched. Recently, the association of HCV infection with hypertrophic or dilated cardiomyopathy and myocarditis in patients has been recognised [9,10]. Moreover, we have established a relation between HCV infection and LV systolic and diastolic dysfunction and LV hypertrophy in our previous studies [6,11].

To our knowledge, so far there has been no study evaluating right ventricular systolic function and pulmonary hypertension in HCV patients. Our present study was conducted to explore any changes in systolic function of the right ventricle, pulmonary artery pressure and pulmonary vascular resistance (PVR) in HCV infected patients.

Materials and Methods

Selection of the patients

Fifty patients (with mean age 34±12 years), who has been followed in the outpatient clinic of infection diseases department because of chronic hepatitis C (anti-HCV and HCV-RNA positive for at least 6 months), has normal
liver enzymes and has not received antiviral treatment, were selected for the study.

The control group consisted of 50 persons, (with mean age 28±11 years) who appealed to the cardiology and infectious disease outpatient clinic because of various reasons and did not have any identified structural cardiac pathologies. A physical examination, the medical history of patients, and the blood biochemistry were evaluated in all groups. The subjects were defined as hypertensive if their blood pressure was ≥140/90 mmHg or if they were receiving any antihypertensive medication. Diabetes mellitus was defined as the presence of a history of antidiabetic medication usage or fasting glucose level > 126 mg/dl. Smoking status was classified as smokers or those who never smoked.

Patients with coronary artery disease, heart failure, valvular disease, cardiomyopathy, hypertension, diabetes mellitus, chronic lung disease, sleep apnoea, thyroid dysfunction, anemia, malignancy, renal and hepatic insufficiency, chronic inflammatory disease, pregnancy, septicemia, cerebrovascular accident were excluded from the study. Intravenous drug abusers, alcohol drinkers, HIV and hepatitis B virus carriers were also excluded. All of the patients were in sinus rhythm and none of them were taking cardioactive medications like antiarrhythmics, antiplatelet, antipsycotics, and antihistaminics. Every patient signed an informed consent form and the local ethics committee approved the study.

**Echocardiographic Measurements**

Two-dimensional, M-mode, pulsed and colour flow Doppler echocardiographic examinations of all subjects were performed by the same examiner with a commercially available machine (Vivid 7 pro, GE, Horten, Norway, 2-4 mHz phased array transducer). During echocardiography, a one-lead electrocardiogram was used.

M-mode measurements were performed according to the criteria of American Society of Echocardiography and European Associated Echocardiography [14]. PVR was calculated using (TR max velocity/RVOTVt) x 10 +0.16 [15].

**Statistical Analyses**

SPSS 16.0 statistical program (SPSS, Chicago, IL, USA) was used for statistical study. All values are given as mean ± standard deviation. Values between different groups were compared using the independent-samples t-test. A Chi-square test was used to assess differences between categorical variables. The relationship between parameters was determined using the Pearson coefficient of correlation. P-values <0.05 were considered significant.

**Results**

There was no statistically significant difference between the HCV group and controls with regard to age, gender, blood pressure, body surface area, smoking status, diameters of the left atrium and the left ventricle and left ventricular systolic and diastolic parameters (Table 1).

In HCV positive group, the RV FAC, TAPSE and St values were found to be lower (34 ± 10 vs 62 ±13 % and 15.3 ± 2.1 vs 23.4 ± 3.3 mm, and 9.1 ± 1.1 vs 16.2 ± 2.4 cm/s, all p<0.001, respectively); MPI, which shows both systolic and diastolic functions, was found to be higher in the patient group compared to the controls (0.47 ±0.7 vs 0.33 ± 0.2, p<0.001). The RA and RV diameters were found to be higher (4.8 ± 1.3 vs 3.4 ± 0.6cm and 4.3 ± 0.8 vs 3.2 ± 0.5 cm both p<0.001, respectively); additionally systolic pulmonary artery pressure (SPAP) and PVR were found to be higher (36.3 ± 9.9 vs 23.1 ± 8 mmHg, and 3.5 ± 1.1 vs 2.1± 0.8; p<0.001, respectively). Also RV E/e' ratio which shows diastolic dysfunction significantly higher in the HCV patients (9.3 ± 2.4 vs 5.2 ±1.5, p<0.001). No other statistically significant difference was found between the two groups with regard to the right ventricular diastolic parameters (Table 2).
Hepatitis C virus and right heart failure

**Table 1.** Comparison of clinical and echocardiographic features of HCV patients and controls group

<table>
<thead>
<tr>
<th></th>
<th>Patients (N=50)</th>
<th>Controls (N=50)</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>34 ± 12</td>
<td>28 ± 11</td>
<td>NS</td>
</tr>
<tr>
<td>Male (n,%)</td>
<td>25 (50)</td>
<td>20 (40)</td>
<td>NS</td>
</tr>
<tr>
<td>BSA (m²)</td>
<td>1.9 ± 0.3</td>
<td>1.9 ± 0.2</td>
<td>NS</td>
</tr>
<tr>
<td>LV EF (%)</td>
<td>58 ± 9</td>
<td>64 ±11</td>
<td>NS</td>
</tr>
<tr>
<td>LA diameter(cm)</td>
<td>3.5 ± 0.8</td>
<td>3.2 ± 0.6</td>
<td>NS</td>
</tr>
<tr>
<td>LV EDD (cm)</td>
<td>4.6 ± 1.9</td>
<td>4.3 ± 5.5</td>
<td>NS</td>
</tr>
<tr>
<td>LV ESD (cm)</td>
<td>2.9 ± 0.9</td>
<td>2.5 ± 0.7</td>
<td>NS</td>
</tr>
<tr>
<td>E/A</td>
<td>1.3 ± 0.4</td>
<td>1.2 ± 0.2</td>
<td>NS</td>
</tr>
<tr>
<td>E/e’</td>
<td>9.1 ± 1.1</td>
<td>6.7 ± 0.9</td>
<td>NS</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>120 ± 13</td>
<td>122 ± 16</td>
<td>NS</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>74 ± 15</td>
<td>77 ± 9</td>
<td>NS</td>
</tr>
<tr>
<td>Smoking (n)</td>
<td>9</td>
<td>10</td>
<td>NS</td>
</tr>
</tbody>
</table>

BSA: body surface area, LA: left atrium, LVEF: left ventricular ejection fraction LVEDD: left ventricular end-diastolic dimension, LVESD: left ventricular end-systolic dimension, e’: mean LV myocardial early diastolic velocity, SBP: systolic blood pressure, DBP: diastolic blood pressure.

**Table 2.** Conventional and Tissue Doppler Right Ventricular Echocardiographic Parameters

<table>
<thead>
<tr>
<th></th>
<th>Patients (N=50)</th>
<th>Controls (N=50)</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>RA diameter (cm)</td>
<td>4.8 ± 1.3</td>
<td>3.4± 0.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>RV diameter (cm)</td>
<td>4.3 ± 0.8</td>
<td>3.2 ± 0.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>RV E/A</td>
<td>1.1 ± 0.3</td>
<td>1.3 ±0.5</td>
<td>NS</td>
</tr>
<tr>
<td>RV DT (ms)</td>
<td>186 ± 16</td>
<td>175 ± 14</td>
<td>NS</td>
</tr>
<tr>
<td>RV E/e’</td>
<td>9.3 ± 2.4</td>
<td>5.2 ±1.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>RV MPI</td>
<td>0.47 ± 0.7</td>
<td>0.33 ± 0.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>RV FAC (%)</td>
<td>34 ± 11</td>
<td>62 ±13</td>
<td>0.001</td>
</tr>
<tr>
<td>TAPSE (mm)</td>
<td>15.3 ± 2.1</td>
<td>23.4 ± 3.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>St (cm/s)</td>
<td>9.1 ± 1.1</td>
<td>16.2 ± 2.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>SPAP (mmHg)</td>
<td>36.3 ± 9.9</td>
<td>23.1 ± 8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PVR (Wood)</td>
<td>3.5 ± 1.1</td>
<td>2.1 ±0.6</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

RA: right atrium, RV: right ventricle, DT: deceleration time, RV e’: mean RV myocardial early diastolic velocity, MPI: myocardial performance index, RV FAC: right ventricular fraction area change, TAPSE: tricuspid anular plane excursion, St:mean RV systolic myocardial velocity, SPAP: systolic pulmonary artery pressure, PVR: pulmonary vascular resistance.

**Discussion**

This study revealed that pulmonary systolic pressure and PVR were higher in HCV patients than in controls. Also there is a relationship between RV systolic dysfunction and HCV.

Recently, the importance of HCV infection in myocarditis and cardiomyopathy has been emphasised. HBV and HCV has been associated with atherosclerosis and HCV sero-positivity in patients with coronary artery disease and this was found to be related to cardiac failure and increased mortality[16]. Matsumori et al.[17] found anti-HCV positivity in 10.6% of the patients with hypertrophic cardiomyopathy and in 6.3% of the patients with dilated cardiomyopathy. Additionally, they found arrhythmia in 21.5% of anti-HCV positive patients. Hence, the authors suggested that HCV might play a role in several cardiac disorders with formerly unidentifiable etiology.

In our previous study, an association was also found between HCV infection and the left ventricular hypertrophy, in terms of the left ventricular systolic and diastolic dysfunction [6,11]. Wang et al.[18] found higher NT-proBNP levels, increasing with heart failure in the HBV/HCV patients not having liver failure, in comparison with the control group.

Recent studies revealed that there is a relation between HCV and lung disease such as pulmonary fibrosis, chronic obstructive pulmonary disease and interstitial pneumonitis [7,8].

Biomed Res- India 2015 Volume 26 Issue 1
According to this situation, it is considered that HCV infections may increase heart failure and pulmonary dysfunctions. Despite a large number of studies done about the relation between cardiomyopathy and heart failure, the data about cardiac and pulmonary effects of HCV is limited.

In our study, we found lower RV FAC, TAPSE, St and higher MPI; which indicates RV systolic dysfunction in the patient group. Similarly a significantly high E/e' ratio also indicated diastolic dysfunction in the HCV patients. In this study, we found a relationship between HCV infection and RV systolic and diastolic dysfunction. Also PASP and PVR were found higher than the control group. It may be considered that this situation causes RV systolic dysfunction, pulmonary dysfunction and portal hypertension due to hidden liver failure. Moreover, there may be some bioactive substances that we have not recognized yet, which may lead to obscure hepatic failure with normal AST/ALT and consequently are not metabolized in the liver and affect only RV, but not LV, since they are metabolized in the lungs; furthermore, hepatic failure may lead to portopulmonary hypertension and consequent RV dysfunction without manifesting clinical symptoms.

Limitations of the study
The most significant limitation of our study is the insufficient number of the patients. Other limitations include single transthoracic echocardiography assay, except physical examination other tests and evaluations were not performed for lung disease and sleep apnoea. Also for hepatic failure, other than AST and ALT further evaluation and imaging studies were not performed.

Conclusion
Our findings showed that HCV infection seems to be associated with the RV systolic dysfunction and pulmonary artery hypertension although the mechanisms of these are not known thoroughly. Therefore, cardiac involvement and pulmonary hypertension should be considered during the follow-up of a patient with HCV infection for extra hepatic involvement and these patients should be monitored with echocardiography. Further-more, HCV should be kept in mind for the patients who have cardiomyopathy, right cardiac failure and pulmonary hypertension with unidentifiable etiology. Further comprehensive studies may be needed to confirm our findings.

Conflict of interest
none declared

References
Hepatitis C virus and right heart failure


Correspondence to:

Mehmet Demir
Yaseminpark sit
4-E blok D:11
Osmangazi 16100
Bursa/Turkey